These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32777322)

  • 1. Impact of COVID-19 on global HCV elimination efforts.
    Blach S; Kondili LA; Aghemo A; Cai Z; Dugan E; Estes C; Gamkrelidze I; Ma S; Pawlotsky JM; Razavi-Shearer D; Razavi H; Waked I; Zeuzem S; Craxi A
    J Hepatol; 2021 Jan; 74(1):31-36. PubMed ID: 32777322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Coronavirus Disease 2019 Pandemic on Viral Hepatitis Elimination: What Is the Price?
    Sowah L; Chiou C
    AIDS Res Hum Retroviruses; 2021 Aug; 37(8):585-588. PubMed ID: 33913731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline.
    Mårdh O; Quinten C; Amato-Gauci AJ; Duffell E
    Infect Dis (Lond); 2020 Sep; 52(9):625-637. PubMed ID: 32644030
    [No Abstract]   [Full Text] [Related]  

  • 4. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
    J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; D'Offizi G; Craxì A
    Liver Int; 2023 Dec; 43(12):2615-2624. PubMed ID: 37735959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A micro-elimination approach to addressing hepatitis C in Turkey.
    Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
    BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
    Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
    Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
    J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model of the economic benefits of global hepatitis C elimination: an investment case.
    Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
    PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
    PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.
    Kondili LA; Craxì A; Aghemo A
    Liver Int; 2021 Apr; 41(4):649-655. PubMed ID: 33486885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global investment framework for the elimination of hepatitis B.
    Howell J; Pedrana A; Schroeder SE; Scott N; Aufegger L; Atun R; Baptista-Leite R; Hirnschall G; 't Hoen E; Hutchinson SJ; Lazarus JV; Olufunmilayo L; Peck R; Sharma M; Sohn AH; Thompson A; Thursz M; Wilson D; Hellard M
    J Hepatol; 2021 Mar; 74(3):535-549. PubMed ID: 32971137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.